Advertisement

Topics

First-Line Nivolumab in Advanced Lung Cancer Fails to Improve Outcomes

20:00 EDT 1 Jul 2017 | Cancer Networks

Nivolumab did not extend progression-free survival over chemotherapy in the first-line setting in patients with PD-L1–positive advanced non–small-cell lung cancer, according to results of an open-label phase III trial.

Original Article: First-Line Nivolumab in Advanced Lung Cancer Fails to Improve Outcomes

NEXT ARTICLE

More From BioPortfolio on "First-Line Nivolumab in Advanced Lung Cancer Fails to Improve Outcomes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...